2seventy bio, Inc. (TSVT)

4.6000 +0.0400 (+0.88%) At close: 04:00PM EDT

2seventy bio, Inc.

60 Binney Street
Cambridge, MA 02142
United States
617 675 7270
https://www.2seventybio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 274

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. William D. Baird III, M.B.A.	CEO, President & Director	708k	N/A	1972
Ms. Victoria Eatwell	Chief Financial Officer	N/A	N/A	1986
Ms. Jessica Snow	Senior VP of Quality and Head of Operations	N/A	N/A	1979
Anna Truppel-Hartmann	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

2seventy bio, Inc.’s ISS Governance QualityScore as of April 29, 2024 is 8. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.